| Home | E-Submission | Sitemap | Editorial Office
top_img
Korean J Hepatol > Volume 13(3); 2007 > Article
The Korean Journal of Hepatology 2007;13(3): 349-362.
doi: https://doi.org/10.3350/kjhep.2007.13.3.349
Effect of Initial Virologic Response to Adefovir on the Development of Resistance to Adefovir in Lamivudine-resistant Chronic Hepatitis B
In Hee Kim , Seong Hun Kim , Hyun Chul Kim , Kyoung Deok Shin , Sang Wook Kim , Seong Ok Lee , Soo Teik Lee , Dae Ghon Kim
Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea
Abstract

Background/Aims:
Adefovir dipivoxil (ADV) resistance in patients with lamivudine-resistant chronic hepatitis B is not well understood. This study examined the initial virologic response (IVR) to ADV, the rate of ADV resistance and the factors associated with ADV resistance.
Methods:
Eighty one lamivudine-resistant HBeAg-positive patients were enrolled in this study. IVR was defined as HBV DNA < 4 log10 copies/mL after 6 months of therapy.
Results:
IVR was observed in 37/81(45.7%) patients and it was associated with higher pretreatment ALT (P=0.002), and low pretreatment HBV DNA level (P=0.015). The HBV DNA levels were significantly higher in the non-IVR patients than the IVR patients at 12, 18 and 24 months (4.73 vs 2.59, 4.53 vs 2.31, 4.39 vs 2.40 log10 copies/mL, respectively; P<0.01). During the follow-up period, 17(21.0%) patients showed phenotypic resistance to ADV and 9 (11.1%) patients had ADV-resistant mutations. The cumulative probabilities of the phenotypic resistance to ADV at 12 and 24 months were 8.7% and 32.5%, respectively. The cumulative probabilities of the genotypic resistance to ADV at 12 and 24 months were 0% and 14.6%, respectively. Resistance to ADV was associated with a higher pretreatment HBV DNA (P=0.019), and non-IVR (P<0.001).
Conclusions:
The cumulative probabilities of the phenotypic and genotypic resistance to ADV at 24 months were 32.5% and 14.6%. The high pretreatment HBV DNA and non-IVR (HBV DNA ≥ 4 log10 copies/mL after 6 months of therapy) were associated with ADV resistance. (Korean J Hepatol 2007;13: 349-362)
KeyWords: Adefovir; Drug resistance; Hepatitis B, chronic; Lamivudine
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
  E-Mail
Share:      
METRICS
1
Crossref
2
Scopus
1,181
View
1
Download
Related articles
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients  2011 December;17(4)
Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients  2015 June;21(2)
Efficacy and predictors of the virologic response to entecavir therapy in nucleoside naive patients with chronic hepatitis B  2010 March;16(1)
Predictors for virologic response in management of chronic hepatitis B  2010 March;16(1)
Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, Lamivudine-resistant chronic hepatitis B patients  2009 March;15(1)
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association for the Study of the Liver. All rights reserved.